Searched for
BBIL
CCI approves Bharat Biotech International-Eastman Exports dealThe deal has been approved under the green channel route, wherein a transaction which does not raise any risk of an appreciable adverse eff...- BBV154: What you need to know about Bharat Biotech's nasal Covid vaccineIt may produce local antibodies in the upper respiratory tract - which could provide the potential to reduce infection and transmission.
- Bharat Biotech expects regulator's nod for intranasal COVID-19 vaccine in August"We will be applying for licenses and (they) should come. If everything goes well, we know by next month (August). You (people) would rathe...
- India’s vaccine development journey: A triumph of the collectiveIn hindsight, the pandemic indeed stretched our endurance to the hilt. Nevertheless, our will to live and save more lives emerged stronger,...
- View: Serum Institute and Bharat Biotech’s bad mathDid the experts ever do any due diligence to ascertain the actual manufacturing capacity of the two companies they were almost entirely dep...
- Bharat Biotech signs pact with GCVCDrug substance is the pure material that stimulates any pharmacological action. It is the most important ingredient in a drug and is also k...
- More information required from Bharat Biotech for emergency use listing of Covaxin, says WHOWHO website said Bharat Biotech submitted EOI (Expression of Interest) on April 19 and that “More information required”.
- Bharat Biotech submitted 90 per cent of documents to WHO for emergency use listing for Covaxin: SourcesSources also said that no country has instituted a 'vaccine passport' and that countries around the world have their own requirements for a...
- No financial aid given to SII & Bharat Biotech: Govt in SCCentre also informed the court that it has given 100% advance money to Bharat Biotech and SII, totalling Rs 2,520 crore, for procurement of...
- Covaxin can neutralise double mutant variantPhase 3 clinical trials of Covaxin by Bharat Biotech International Ltd (BBIL) and ICMR have demonstrated 100% efficacy against severe Covid...
- Covaxin shows 100% efficacy against severe Covid-19, works well on variants“The tireless efforts of our scientists at ICMR and BBIL have resulted in a truly effective international vaccine of the highest standards ...
- Bharat Biotech, Biovet, Sapigen Biologix sign collaborative research agreement with CSIR-IICTThe Master Collaborative Agreement (MCA) was signed here by Bharat Biotech International, Biovet, Sapigen Biologix with the IICT in the pre...
- Bharat Biotech's intranasal vaccine to enter phase I/II trials by month-endVaccine producer Bharat Biotech International (BBIL) could begin phase I/II human clinical trials for its single-dose intranasal vaccine ca...
- Bharat Biotech promoters buy back ICICI Venture's stakeThe BBIL promoters headed by Dr Krishna Ella have bought 47.06% of the company’s optionally convertible preference shares from ICICI Ventur...
- Bharat Biotech will manufacture 10 types of vaccines at Odisha unitBBIL is a multi-dimensional biotechnology organisation specializing in manufacture of vaccines and bio-therapeutics, Ella said.
- ICMR-Bharat Biotech COVID-19 vaccine trial results to be released by Aug 15A total of 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered the topmost pri...
- ICMR teams up with Bharat Biotech to develop COVID-19 vaccineThe vaccine will be developed using the virus strain isolated at the ICMR's National Institute of Virology (NIV), Pune, a statement said. T...
- Hope to get nasal vaccine against Covid-19 into market in 12-18 months: Hyderabad-based Bharat BiotechKrishna M Ella, a molecular biologist and chairman and managing director of the Bharat Biotech, spoke to TOI's Surendra Singh in an exclusi...
- Biocon board approves sale of branded formulations business to subsidiaryThe Board of Directors in its meeting approved the sale of Branded Formulations India (BFI) business to Biocon Biologics India (BBIL).
- FIPB defers Hind Lever move, awaits nod on FDIThe foreign investment promotion board (FIPB) has deferred Hindustan Lever's proposal for raising FII shareholding from 24 per cent to 49 p...
Load More
